Biogen Statistics
Share Statistics
Biogen has 146.38M
shares outstanding. The number of shares has increased by 0.53%
in one year.
| Shares Outstanding | 146.38M |
| Shares Change (YoY) | 0.53% |
| Shares Change (QoQ) | 0.45% |
| Owned by Institutions (%) | 90.15% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,021 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 3.45M, so 2.35% of the outstanding
shares have been sold short.
| Short Interest | 3.45M |
| Short % of Shares Out | 2.35% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 1.68 |
Valuation Ratios
The PE ratio is 13.65 and the forward
PE ratio is 7.84.
Biogen's PEG ratio is
0.34.
| PE Ratio | 13.65 |
| Forward PE | 7.84 |
| PS Ratio | 2.3 |
| Forward PS | 1.9 |
| PB Ratio | 1.33 |
| P/FCF Ratio | 8.86 |
| PEG Ratio | 0.34 |
Financial Ratio HistoryEnterprise Valuation
Biogen has an Enterprise Value (EV) of 26.54B.
| EV / Sales | 2.74 |
| EV / EBITDA | 0 |
| EV / EBIT | 9.23 |
| EV / FCF | 10.55 |
Financial Position
The company has a current ratio of 1.35,
with a Debt / Equity ratio of 0.4.
| Current Ratio | 1.35 |
| Quick Ratio | 0.9 |
| Debt / Equity | 0.4 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.64 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 9.76% and Return on Invested Capital is 18.46%.
| Return on Equity | 9.76% |
| Return on Assets | 5.82% |
| Return on Invested Capital | 18.46% |
| Revenue Per Employee | $1,272,307.69 |
| Profits Per Employee | $214,621.96 |
| Employee Count | 7,605 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 273.8M |
| Effective Tax Rate | 14.37% |
Stock Price Statistics
The stock price has increased by -44.99% in the
last 52 weeks. The beta is 0.06, so Biogen's
price volatility has been higher than the market average.
| Beta | 0.06 |
| 52-Week Price Change | -44.99% |
| 50-Day Moving Average | 131.65 |
| 200-Day Moving Average | 164.54 |
| Relative Strength Index (RSI) | 46.53 |
| Average Volume (20 Days) | 1,779,835 |
Income Statement
In the last 12 months, Biogen had revenue of 9.68B
and earned 1.63B
in profits. Earnings per share was 11.2.
| Revenue | 9.68B |
| Gross Profit | 9.68B |
| Operating Income | 5.23B |
| Net Income | 1.63B |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | 11.2 |
Full Income StatementBalance Sheet
The company has 2.38B in cash and 6.63B in
debt, giving a net cash position of -4.26B.
| Cash & Cash Equivalents | 2.38B |
| Total Debt | 6.63B |
| Net Cash | -4.26B |
| Retained Earnings | 19.26B |
| Total Assets | 28.03B |
| Working Capital | 2.33B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 2.88B
and capital expenditures -359.8M, giving a free cash flow of 2.52B.
| Operating Cash Flow | 2.88B |
| Capital Expenditures | -359.8M |
| Free Cash Flow | 2.52B |
| FCF Per Share | 17.27 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of 54.06% and 16.87%.
| Gross Margin | 100% |
| Operating Margin | 54.06% |
| Pretax Margin | 19.7% |
| Profit Margin | 16.87% |
| EBITDA Margin | n/a |
| EBIT Margin | 54.06% |
| FCF Margin | 26% |
